
DB1976
CAS No. 1557397-51-9
DB1976( —— )
Catalog No. M32877 CAS No. 1557397-51-9
DB1976 is a selenophene analog of DB270 and a highly potent, cell-permeable, fully efficacious transcription factor PU.1 inhibitor.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
2MG | 179 | Get Quote |
![]() ![]() |
5MG | 226 | Get Quote |
![]() ![]() |
10MG | 335 | Get Quote |
![]() ![]() |
25MG | 522 | Get Quote |
![]() ![]() |
50MG | 707 | Get Quote |
![]() ![]() |
100MG | 888 | Get Quote |
![]() ![]() |
200MG | 1251 | Get Quote |
![]() ![]() |
500MG | Get Quote | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NameDB1976
-
NoteResearch use only, not for human use.
-
Brief DescriptionDB1976 is a selenophene analog of DB270 and a highly potent, cell-permeable, fully efficacious transcription factor PU.1 inhibitor.
-
DescriptionDB1976 is a selenophene analog of DB270 and a potent and cell-permeable fully efficacious transcription factor PU.1 inhibitor. DB1976 potently inhibits PU.1 binding (IC50 of 10 nM) and strongly inhibits the PU.1/DNA complex (with high DB1976-λB affinity, KD of 12 nM) in vitro. DB1976 has apoptosis-inducing effect.
-
In VitroDB1976 is a classic heterocyclic dication (a single heteroatom) with strong affinity and selectivity for AT-rich sequences commonly found in cognate DNA binding sites for PU.1. DB1976 inhibits PU.1-dependent transactivation of the reporter in a dose-dependent manner with an IC50 value of 2.4 μM in PU.1-negative HEK293 cells.DB1976 treatment leads to a profound decrease in the growth of PU.1 URE–/– AML cells (IC50 of 105 μM), while showing little effect on normal hematopoietic cells at similar concentrations (IC50 of 334 μM). DB1976 treatment leads to a 1.6-fold increase in apoptotic cells in murine PU.1 URE–/– AML cells, and observed similar effects in human MOLM13 cells.DB1976 treatment leads to a significant decrease in the number of viable cells (primary human AML cells) (mean decrease of 81%) and clonogenic capacity (mean decrease of 36%) compared with vehicle-treated cells. The apoptotic cell fraction increased on average by 1.5-fold with DB1976.
-
In Vivo——
-
Synonyms——
-
PathwayApoptosis
-
TargetApoptosis
-
RecptorApoptosis
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1557397-51-9
-
Formula Weight447.35
-
Molecular FormulaC20H16N8Se
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESC(=N)(N)C=1C=C2NC(=NC2=CC1)C=3[Se]C(=CC3)C=4NC=5C(N4)=CC=C(C(=N)N)C5
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference



-
Anticancer agent 110
Anticancer Agent 110 exhibits potent in vitro anti-leukemia activity, demonstrating high cytotoxicity against K-562 lineage chronic myelogenous leukemia cells at nanomolar concentrations.
-
CCCI-01
CCCI-01(Centrosome Clustering Chemical Inhibitor-01) is a centrosome cluster inhibitor. CCCI-01 has anticancer activity, induces apoptosis, and can be used in the study of non-cross-resistant anticancer compounds that block centrosome clustering.
-
Puromycin aminonucle...
Puromycin aminonucleoside increases podocyte permeability by modulating ZO-1 in an oxidative stress-dependent manner.Puromycin aminonucleoside -induced podocyte apoptosis is p53 dependent. Puromycin aminonucleoside causes podocyte apoptosis in a time-dependent manner.